Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of Theravance Biopharma (NASDAQ: TBPH) after hosting management for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE